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1. Introduction 
Most of head and neck cancer (HNC) are squamous cell carcinoma. Recent advances in 
molecular biology have documented significant genetic differences between  head and neck 
squamous cell carcinoma (HNSCC) cells and normal cells, leading to the development of 
potential new therapeutics and chemoprevention (Choi & Myers, 2008). Historically, the 
association between inflammation and cancer has been recognized.  More recently, a 
number of chronic inflammatory diseases have been shown to be associated with a variety 
of human cancers, including HNC (Conroy et al., 2010; Fitzpatrick & Katz, 2010).  The 
relationship between oral health and cancer has been examined for a number of specific 
cancer sites. Several studies have reported associations between periodontal disease or tooth 
loss and risk of oral, upper gastrointestinal, lung, and pancreatic cancer in different 
populations (Meyer et al., 2008). Cumulating evidences support the view that inflammatory 
mediators, some of that may downregulate DNA repair pathways directly or indirectly. 
Certain inflammatory mediators may affect on cell cycle checkpoints that result in the 
accumulation of random genetic alterations. These in turn lead to a genomically 
heterogenous population of expanding cells naturally selected for their ability to proliferate, 
invade and evade hose defenses (Colotta et al., 2009). 
Molecular studies of the well-known relationship between polyunsaturated fatty acid 
metabolism and carcinogenesis provide novel molecular targets for cancer chemoprevention 
and treatments. Several classes of agents have shown promise as chemopreventive agents, 
including the nonsteroidal anti-inflammatory drugs (NSAIDs), which posses a valid scientific 
basis for the prevention of multiple cancers, including HNC. Because NSAIDs are well-
accepted inhibitors of cyclooxygenase (COX) and prostaglandin (PG) production, research 
work initially focused on COX-and PG-dependent mechanism of NSAIDs actions. 
Polyunsaturated fatty acid, including arachidonic and linoleic acids, can enhance 
tumorigenesis (Shureiqi & Lippman, 2001).  Aberrant arachidonic acid (AA) metabolism, 
especially COX-2 and 5-lipoxygenase (5-LOX) pathways, are activated during oral 
carcinogenesis, and can be targeted for cancer prevention (el-Hakim & Langdon, 1991).  
Recently, we found that inhibition of AA metabolism caused a decrease in HNSCC cell 
invasion and matrix metalloproteinase (MMP) activities. Our findings suggest the contributory 
roles of COX and LOX in HNC development and progression (Koontongkaew et al., 2010).  
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This review will briefly summarize the implication of AA metabolism in HNC. We will 
discuss what are known of COX and LOX in tumorigenesis of HNC. Possible mechanisms of 
action of COX and LOX and potential roles for AA inhibitors in the prevention and therapy 
of this cancer will be documented in this review. 
2. Arachidonic acid cascade 
AA is a long chain polyunsaturated fatty acid containing 20 carbons. It can be stored in 
membrane phospholipids and released from nuclear envelop or plasma membrane by 
cytosolic phospholipase A2 (cPLA2), either constitutively or in respond to a variety of cell 
specific stimuli, including growth factors, hormones, cytokines, signaling molecules, or cell 
trauma. Free AA can be subsequently metabolized by three key enzymes, COX, LOX, or 
cytochrome P450 (CYP450) to generate lipid mediators, eicosanoids, which involved in 
various biological function, inflammation regulation, and more recently, tumor progression 
(Funk, 2001; Wang et al., 2007; Hyde & Missailidis, 2009). COX metabolism generates 
prostanoids, including prostaglandins (PGs) and thromboxanes (TXs). LOX generates 
leukotrienes (LTs), lipoxin (LXs) and hepoxillins (HOs). CYP450 metabolic pathway gives a 
family of lipoxygenase-like hydroeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids 
(EETs) and ω-HETEs (Capdevila et al., 2000). 
2.1 The COX pathway 
In the COX pathway, COX first oxidized AA to form prostaglandin G2 (PGG2), and is then 
metabolized into an intermediate prostaglandin H2 (PGH2) by peroxidase activity (Figure 1). 
PGH2 is an unstable endoperoxide, which is catalyzed to five primary prostanoids, 
including PGD2, PGE2, PGF2ǂ, PGI2 and thromboxane A2 by specific synthases.  
Three isoforms of COX have been identified, COX-1, COX-2 and COX-3 (Williams et al., 
1999; Wang et al., 2007). COX-1 and COX-2 are similar in structure and catalytic activity. 
Both enzymes have the same molecular weight and share a 61% amino acid sequence 
homology. COX-3 is the splice variants of COX-1, which retains intron 1 and has a 
frameshift mutation (Wang et al., 2007). COX-3 was constitutively highest expressed in the 
cerebral cortex and heart tissue (Chandrasekharan et al., 2002). COX-1 is constitutively 
expressed in almost all tissues and resident inflammatory cells. It generates PGs that 
control homeostasis. COX-2 is normally undetectable. Constitutive COX-2 expression is 
well recognized in brain, kidney and the female reproductive tract.  However, COX-2 is 
the most important regulator in the respond to inflammation and many types of cancers. 
COX-2 can be induced by multiple cytokines and growth factors, via activation of 
transcription factors that act on the promoter region, including TATA box, and NF-IL6 
motif, two AP-2 sites, three Sp1 sites, two NF-κB sites, a CRE motif and an E-box  
(Park et al., 2006). 
The PGEs subclass, including cytosolic PGE synthase (cPGEs) and membrane-bound PGE 
synthases (mPGEs), is also involved in inflammation and carcinogenesis. Once the various 
PGs are synthesized, they are exported into the extracellular microenvironment and bind to 
the specific G-protein coupled receptors (GPCRs) that can be activated by autocrine and 
paracrine fashions in the tumor microenvironment (Sugimoto & Narumiya, 2007).  
www.intechopen.com
 
Arachidonic Acid Metabolism and Its Implication on Head and Neck Cancer 
 
169 
 
Fig. 1. Main products and enzymes of the COX pathway. COX: cyclooxygenase; PG: 
prostaglandin; TX: thromboxane. 
3. COX and HNC 
In the last decade inflammation and cancer had been linked together as biomarkers and 
novel targets of cancer therapy in a large number of cancers, including HNC. 
Overexpressions of COX-2 and prostanoids have been shown in various forms of human 
cancers, including HNC, and they can be linked with cancer progression and metastasis (Lee 
et al., 2001; Krysan et al., 2004; Huh et al., 2009). COX-2 expression was correlated with 
shorter survival in non-small cell lung cancer and poor survival in prostate cancer and 
gliomas patients (Khuri et al., 2001; Shono et al., 2001; Khor et al., 2007).   Upregulation of 
COX-2 has been reported in human tissues and cell lines as well as in serum of patients with 
HNC. The increased levels of COX-2 were associated with the risk of tobacco- and betel nut-
related cancers, advance clinical stage, survival and lymph node metastasis (Tang et al., 
2003; Molinolo et al., 2007; Chiang et al., 2008; Husvik et al., 2009; Saba et al., 2009; Kapoor et 
al., 2010; Mittal et al., 2010). In addition, PGE2 receptors are widely expressed in a variety of 
HNSCC  cell lines as well as in tumor tissues (Abrahao et al., 2010). 
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Several studies showed the effects of COX inhibitors on cancer cell proliferation, invasion 
and proliferation, invasion and metastasis. Selective COX-2 inhibitors decreased viability, 
invasion and adhesion of HNSCC cells by down-regulated MMP-2, MMP-9 and vascular 
endothelial growth factor (VEGF) secretion (Kim et al., 2010; Koontongkaew et al., 2010; Li et 
al., 2010). Moreover, suppression of COX-2 expression by small RNAs reduced cancer cell 
proliferation and invasion by decreased VEGF production (Park et al., 2010; Wang et al., 
2010).  Selective COX-1 inhibitor also decreased cancer cell proliferation (Koontongkaew et 
al., 2010). However, little is known about the molecular mechanism of the COX-2 pathway 
in the regulation of HNSCC cell growth. Molecular mechanism of cell apoptosis by COX-
2/PGE2 through phosphatidylinositol 3-kinase (PI3K)/AKT pathway has been suggested in 
human epidermoid carcinoma cells (Agarwal et al., 2009).  
COX-2 is expressed in tumor neovasculature as well as in tumor tissues. The proangiogenic 
factors of COX-2 are TXA2, PGI2 and PGE2. Selective inhibitor of COX-2 has been shown to 
suppress angiogenesis in vitro and in vivo by reduced VEGF production (Williams et al., 
2000). This suggests a role of COX in the process of angiogenesis, which might have an effect 
in HNSCC cell proliferation. 
3.1 COX and ERK pathway 
Upregulation of epidermal growth factor receptor (EGFR) has been suggested as a major 
pathway involved in HNSCC progression (Le Tourneau et al., 2007; Molinolo et al., 2009). 
Activation of EGFR has been shown to induce increased COX-2 expression in various 
normal and cancer cell lines, including HNSCC cells. However, the signaling pathway 
involved in COX-2 via EGFR varies depending on the type of cells and inducers, but the 
ras/ raf/ mitogen-activated protein kinases (MAPKs) signaling pathways mainly contribute 
to both increased transcriptional and posttranscriptional controls. On the other hand,  
COX-2 could induce transactivation or upregulate EGFR expression (Choe et al., 2005; 
Husvik et al., 2009).  
Selective COX-2 inhibitors have been shown to decrease PGE2 production in vitro and in vivo 
(Hoshikawa et al., 2009; Abrahao et al., 2010). This implies that upregulated PGE2 in tumor 
microenvironment by COX-2 overexpression may promote the growth of HNSCC cells in an 
autocrine and/or paracrine effects by acting on widely expressed PGE2 receptors in  
HNSCC cells. Additionally, p53, a tumor suppressor, play an inhibitory role in AA 
metabolism. It downregulates COX-2 expression and leads to tumor cell apoptosis 
(Subbaramaiah et al., 1999). 
3.2 COX and PI3K/AKT pathway 
The PI3K/AKT pathway plays critical roles in the control of cancer cell survival and 
apoptosis in many cancers, including HNC (Jiang & Liu, 2008; Cohen et al., 2011). It has been 
recognized that protein kinase B (Akt/PKB) activity is implicated in K-Ras-induced 
expression of COX-2, and the mRNA stability of COX-2 partially depends on the activation 
of AKT (Sheng et al., 2001). Indomethacin, a NSAID, has been found to induce apoptosis in 
renal cell carcinoma cells by activating AKT and MAPK signaling (Ou et al., 2007).  
Celecoxib, a selective COX-2 inhibitor, had been shown to induce apoptosis through 
(PI3K)/AKT and the COX-2 signaling pathway in various cancers, including non-small cell 
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lung carcinoma, prostate and gastric cancers (Kulp et al., 2004; Zhu et al., 2004; Fan et al., 
2006). In HNC, however, the mechanism of COX-2 upregulation is not fully understood. 
There was reported that COX alone did not effect on pEGFR, pERK1/2 and pAKT. 
However, inhibition of combination of COX and EGFR reduced the AKT activities of 
HNSCC cells (Chen et al., 2004b). 
3.3 COX and tumor invasion 
It is well documented that COX inhibitors reduce cancer cell migration, cell adhesion and 
tumor invasiveness (Lin et al., 2002). Increased invasiveness has been associated with 
activation of MMPs. MMPs are a family of proteolytic enzymes linked to several malignant 
properties of a variety of tumor cells, including HNSCC cells (Rosenthal & Matrisian, 2006). 
Therefore, it is possible that COX-2 enhances tumor cell invasion through the upregulated 
MMP activities. To date, however, a few studies have investigated the importance of COX-2 
in modulating the invasive properties of HNSCC cells. Recently, we found that COX-1 and 
COX-2 inhibitors reduced cell viability, MMP-2 and MMP-9 activities, and in vitro invasion 
of primary and metastatic HNSCC cells (Koontongkaew et al., 2010). Our findings are 
consistent with other studies that demonstrated the inhibitory effects of COX inhibitors on 
MMP activities in breast (Larkins et al., 2006), prostate (Attiga et al., 2000), colon (Ishizaki et 
al., 2006) and lung cancer cells (Karna & Palka, 2002). Regarding the role of COX-2 in the 
metastasis and invasion of HNSCC cells, the precise mechanism remains obscure, but a 
decrease of COX-2 dependent PGE2 may downregulate MMP production through PGE2 
receptors (Dohadwala et al., 2002). 
4. Inhibition of COX  
NSAIDs, non-selective inhibitors for COX, are over-the-counter drugs and widely use as 
analgesics, anti-inflammations, antipyretic and chemoprevention in cardiovascular diseases 
and other disorders.  Experimental tumor model studies show that NSAIDs impair the 
growth and development of HNSCC, indicating potential as a chemopreventive agent 
(Cornwall et al., 1983; Lin et al., 2002; Mohan & Epstein, 2003). Moreover, both non-selective 
and selective of COX prevented 4-nitroquinoline- oxide (NQO)-induced tumorigenesis in 
rats (McCormick et al., 2010).   Regular use of aspirin has been shown to reduce the risk of 
colon cancer (Dube et al., 2007). Celecoxib is approved for the chemoprevention of colon 
cancer in patients with familial adenomatous polyposis. This COX-2 inhibitor has also been 
shown to reduce the incidence of various cancers in vivo (Grosch et al., 2006). To date, 
however, no definitive conclusion on the effect of NSAIDs/aspirin use on the risk of 
HNSCC is well documented (Wilson et al., 2011). Although NSAIDs or aspirin may have 
protective effect on HNSCC, further large-scale studies are required.  
Selective COX-2 inhibitors were reported to enhance treatment responds to radiotherapy or 
combination of radiotherapy and chemotherapy, suggesting that the inhibitors can improve 
the response of various cancers to conventional cancer therapies (Liao et al., 2003; Komaki et 
al., 2004). To date, several concurrent clinical trial studies of HNC are using a combination of 
standard treatment with a selective COX-2 inhibitor and the others, such as EGFR inhibitor, 
which has been shown to improve survival in patients with non-small cell lung cancer 
(Fidler et al., 2008).   A combination of EGFR-selective tyrosine kinase inhibitor with a COX-
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2 inhibitor (celecoxib) induced cell cycle arrest and apopotosis in HNSCC cells. The 
combination showed strong reduction of EGFR, ERK1/2 and AKT activations (Chen et al., 
2004b). The phase 1 clinical trial, using a combination of an EGFR inhibitor (erlotinib), a 
selective COX-2 inhibitor (celecoxib) and reirradiation showed a feasible and clinically 
active regimen for recurrent HNC patients (Kao et al., 2011). During and after radiotherapy 
in combination with celecoxib, significant decrease of the plasma levels of VEGF were 
observed in patients with advanced HNC who had high COX-2 expression in their tumor 
tissues (Halamka et al., 2011).  
5. The LOX pathway 
In human cells, generally, four types of LOXs have been identified, namely 5-, 12- and 15-LOX-
1 and LOX-2. Collectively, they catalyze the oxygenation of AA into 
hydroperoxyeicosatetraenoic acids (HPETEs) (Figure 2). Ultimately, this is followed by their 
conversion to their corresponding hydroeicosatetraenoic acids (HETEs), leading to the 
formation of LTs, LXs and HOs.  The metabolism of linoleic acid preferentially results in the 
formation of hydroxyloctadecadienoic acids (HODEs). 5-LOX catalyzes the first step in the 
oxygenation of AA to produce 5-HPETE, and the subsequent metabolism of 5-HPETE to 5-
HETE and LTs. LTs belong to a key group of pro-inflammatory mediators that are synthesized 
from AA via the 5-LOX pathway. The activity of 5-LOX leads to the formation of unstable 
LTA4, which can be converted into LTB4 or cysteinyl LTs (LTC4, LTD4 and LTE4) Platelet-
type 12-LOX (p12-LOX) exclusively uses AA released from glycerol-phospholipid pools to 
synthesize 12S-HPETE and 12S-HETE, whereas leukocyte-type 12-LOX can also synthesize 
15S-HETE and 12S-HETE. In addition to leukocytes and platelets, the expression of 12-LOX 
isozymes has been observed in various types of cells, including smooth muscle cells, 
endothelial cells and keratinocytes. 15-lipoxygeases (15-LOX) can be subdivided into two 
isoforms, namely 15-LOX-1 and 15-LOX-2. 15-LOX-1 is mainly expressed in reticulocytes, 
eosinophils and airway epithelial cells, as well as in macrophages. In terms of enzymatic 
characteristics, 15-LOX-1 preferentially metabolizes linoleic acid primarily to 13S-HODE, but 
also metabolizes AA to 15S-HETE. 15-LOX-2, on the other hand, converts AA to 15S-HETE 
and poorly metabolizes linoleic acid (Romano & Claria, 2003). 
The products of LOX metabolism represent either intermediary products such as HPETE, 
which are transformed enzymatically into secondary products, including LTs, LXs, HOs and 
HETEs, which can act as signaling molecules in their own right or give rise to the 
production of reactive oxygen species (ROS). Signaling of LOX-derived products can occur 
through either G protein coupled cell-surface receptors, in the case of LOs and LTs, or 
through activation of nuclear receptors such as peroxisome proliferator activated receptors 
(PPARs) in the case of HETEs and HODEs (Pidgeon et al., 2007). 
6. LOX and HNC  
Early tumorigenesis studies in animals demonstrated the contributory roles of AA and 
linoleic acid in tumorigenesis. Various LOX products have been linked to tumorigenesis in 
vitro and also in vivo in animal models. In addition, the modulation of LOX metabolism has 
anticarcinogenic effects on tumor development. Therefore, it suggests that LOX modulation 
has been targeted for developing anticarcinogenic agents (Shureiqi & Lippman, 2001). 
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Fig. 2. Main products and enzymes of the LOX pathway. LOX: lipoxygenase; HPETE: 
hydroperoxyeicosatetraenoic acid; HETE: hydroxyeisatetraenoic acid; HOs: Hepoxillins; 
LXs: lipoxins; LT: leukotriene. 
5-LOX, 12-LOX, 15-LOX-1 and 15-LOX-2 were detected in HNSCC cell lines derived from 
primary and metastatic tumors. Therefore, it is not surprised that LOX metabolites, 
including 5-HETE, 12-HETE, 15-HETE and 13-HODE were found in primary and metastatic 
HNSCC cells. However, there was no correlation between LOX isoforms and their 
metabolites in HNSCC cells (Schroeder et al., 2004). The level of LTB4, a metabolite of the 5-
LOX pathway, was found to be higher in oral cancer lesions in human and hamsters (el-
Hakim et al., 1990; Li et al., 2005).  This enzyme was also upregulated in other cancers, 
including prostate (Gupta et al., 2001), pancreatic (Hennig et al., 2002), colon (Ohd et al., 
2003) and esophageal cancers (Chen et al., 2004a). Previous studies in 7,12-
dimethylbenz[a]anthracene (DMBA)-induced hamster oral cancer demonstrated 
overexpression of 5-LOX in the stromal inflammatory cells and epithelial cells at the early 
stages of oral squamous cell carcinogenesis. Moreover, zileuton, a specific 5-LOX inhibitor 
and celecoxib (a specific COX-2 inhibitor), either alone or in combination, had an inhibitory 
effect on the incidence of oral tumor in DMBA-treated animals. Zileuton seems even more 
effective than celecoxib. These findings suggest that the 5-LOX pathway of AA metabolism 
plays an important role in inflammation-associated oral cancer (Li et al., 2005).  
Recently, studies in the mouse model showed that the expression of 5-LOX and COX-2 was 
increased in dysplasia and squamous cell carcinoma of 4-nitroquinoline-1-oxide (4NQO)-
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treated tongues, and further enhanced by ethanol. Fewer tumors were induced in Alox5-/- 
mice, as were cell proliferation, inflammation, and angiogenesis in the tongue, as compared 
with Alox5+/+ mice. COX-2 expression was induced by ethanol in knockout mice, while 5-
LOX and LTA4H expression and LTB4 biosynthesis were dramatically reduced. Moreover, 
ethanol enhanced expression and nuclear localization of 5-LOX and stimulated LTB4 
biosynthesis in human tongue squamous cell lines. These findings suggest that the 
activation of the 5-LOX pathway of AA metabolism involves in oral carcinogenesis  
(Guo et al., 2011). 
Inhibition of AA metabolism (COX-2 and 5-LOX) by curcumin has also been suggested as a 
key mechanism of its anticarcinogenic action in DMBA-induced hamster oral carcinoma (Li 
et al., 2002; Bengmark, 2006). Zyflamed, a product containing 10- concentrate herbal extracts 
significantly reduced infiltration of inflammatory cells, incidence of hyperplasia and 
dysplastic lesions, cell proliferation as well as number of tumors in the DMBA-induced 
hamster cheek pouch model. Furthermore, it was shown that zyflamed reduced LTB4 
formation compared with that of the control (Yang et al., 2008). 
In a long-term carcinogenesis study, topical application of LTB4 enhanced oral 
carcinogenesis by increasing the incidence and sizes of tumors. LTB4 inhibitors significantly 
inhibited oral carcinogenesis, and the anticarcinogenesis as such correlated with reduced 
levels of LTB4 (Sun et al., 2006). An in-vitro study demonstrated that addition of LTB4 to 
RBL-1 cells, a rat leukemia cell line expressing high levels of 5-LOX, could counteract the 
inhibition of cell proliferation produced by a LOX inhibitor (zyflamed) (Yang et al., 2008). 
LOX products were indentified in human mixed saliva and in saliva fractions obtained from 
a parotid or submandibular gland. In glandular saliva, only linoleic acid was detected at 
levels of 20-30 ng/ml. In contrast, mixed saliva showed a linoleic acid concentration of 
around 300 ng/ml, AA levels of around 30 ng/ml, HODE levels between 5 and 10 ng/ml, 
and HETE levels up to 25 ng/ml. By far the most abundant HETE was 12-HETE, and 
incubation experiments with AA showed the presence of a substantial 12-LOX activity in 
human mixed saliva, but not in saliva fractions. Investigating mixed saliva and glandular 
saliva of patients with squamous cell carcinoma in the upper aerodigestive tract and of 
controls; most patients showed elevated levels of free AA and elevated HETE levels. Besides 
a moderate increase in 12-HETE levels, markedly elevated concentrations of 5-HETE and 15-
HETE were observed for the carcinoma patients. Therefore, it is proposed that the level of 
free AA, and the quantitative HETE profile appear to be good markers for the inflammatory 
processes occurring in the oral mucosa and in saliva in response to the development of 
squamous cell carcinoma (Metzger et al., 1995). 
6.1 Molecular mechanisms of LOX-mediated HNC development 
As mentioned above, substantial evidence supports a functional role for LOX-catalyzed AA 
metabolism in HNC development. Pharmacologic and natural inhibitors of LOX have been 
shown to suppress carcinogenesis and tumor growth in a number of experimental models. 
In recent years participation of LOX in the regulation of cell proliferation, apoptosis and 
angiogenesis has emerged.  Many cell pathways are involved in the process by which cells 
choose between growth arrest, apoptosis or survival. The crosstalk of LOX derived products 
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with different growth factor receptor-induced signaling cascades is involved in the 
stimulation of tumor cell growth.  
The aberrant activation of multiple signaling pathways, including EGFR, ras, NFκB, STAT, 
Wnt/ǃ-catenin, TGF-ǃ and PI3K/AKT were observed in HNSCC (Molinolo et al., 2009). 
Oncogenic events in HNC associated with abnormal activation of the PI3K/AKT pathway 
include mutations, allelic loss, or the promoter methylation of the negative regulator 
phosphatase and tensin homolog (PTEN) (Cohen et al., 2011).  LOX metabolites may exert 
their biological effects in an intracrine manner, through the activation of transcription 
factors of the PPAR family, or they may interact with specific trans-membrane G protein-
couple cell surface receptors in an autocrine or paracrine manner (Pidgeon et al., 2007). LOX 
metabolites may involve in ERK1/2, PI3K/AKT cascade, and STAT signaling pathways in 
HNSCC cells (Pidgeon et al., 2007). PTEN may be oxidized and inactivated during AA 
metabolism in cancer cells. Oxidation of PTEN resulted in a decrease of its phosphatase 
activity, favoring increased PI-3, 4, 5-trisphosphate (PIP3) production, activation of AKT and 
phosphorylation of downstream AKT targets. Such activation leads to cell cycle induction 
during HNC development (Covey et al., 2007; Jiang & Liu, 2008).    
Tumor growth does not only depend on increased cell proliferation but also on prolonged 
cell survival through the inhibition of cell death or apoptosis. LOX inhibition has been 
shown to induce apoptosis in cancer cells (Lepage et al., 2010). LOX metabolites may 
enhance cancer cell survival through an increase in Bcl-2. In addition, they can upregulate 
the p-ERK and p-AKT levels, suggesting the involvement of ERK and AKT pathways in the 
LOX-mediated regulation of growth in cancer cells (Agarwal et al., 2009).  However, it was 
found that metabolism of AA by 5-LOX activity promotes survival of cancer cells via 
signaling through PKCε, a pro-survival serine/threonine kinase which is not dependent on 
the AKT and ERK-pathway (Sarveswaran et al., 2011). 
In addition to its role in neoplastic transformation, 5-LOX and its AA metabolite had shown 
to be involved in angiogenesis. 12S-HETE has been shown to be a mitogenic factor for 
microvascular endothelial cells and stimulates endothelial cell migration. Moreover, 12S-
HETE has an ability to induce the expression of VEGF, an important proangiogenic factor, at 
both protein and promoter levels (Pidgeon et al., 2007). 
However, little is known about the role of LOX in HNC cell metastasis. The process of 
tumor invasion by cancer cells involves degradation of the underlying basement membrane, 
which largely made up of collagen IV. MMP-2 and MMP-9 showed substrate specificity 
toward type IV and V collagen and a number of studies have demonstrated a strong 
correlation between MMP expression and metastatic potential (Rosenthal & Matrisian, 
2006). Recently, our findings demonstrated the inhibitory effects of NDGA 
(nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5, 8, 11, 14-
eicosatetraynoic acid, the COX and LOX inhibitor) on cell proliferation, MMP activity and 
invasion in primary and metastatic HNSCC cells (Koontongkaew et al., 2010).  It is possible 
that LOX inhibitors activate PPAR activity and subsequent reduction in MMP-9 signaling 
(Hyde & Missailidis, 2009).  
The ability of tumor cells to generate 12S-HETE is positively correlated to their metastatic 
potential and the increased expression of p12-LOX enhanced the metastatic potential of 
cancer cells. Moreover, 12S-HETE has been found to modulate multi steps of the metastatic 
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process encompassing tumor cell and endothelial cell interactions, tumor cell motility, 
proteolysis and invasion (Furstenberger et al., 2006).  Moreover, LOX may promote tumor 
cell migration through FAK (focal adhesion kinase) activation (Navarro-Tito et al., 2008).   
It should be noted that the role of LOX in HNC development is thought to be more complex, 
compared with that of COX because 6 LOX genes have been identified in human and 
different profiles of LOX were found in studies on human tumor biopsies and 
experimentally induced animal tumor models. The inverse expression pattern of individual 
LOX isoenzymes in normal versus malignant tissues and the biological effects of the 
corresponding LOX products propose the important role of dynamic balance among LOX 
isoenzymes in tumorigenesis. It has been shown a dynamic balance among LOX shifting 
toward the procarcinogenic 5- and p12-LOX and away from anticarcinogenic LOXs  such as 
15-LOX-1, 15-LOX-2, 8-LOX and epidermal-type 12-LOX (e12-LOX) during prostate and 
colon cancer development (Menna et al., 2010). However, at present little is known about 
modulation of carcinogenesis through pro-and anticarcinogenic LOX isoforms in HNC 
development and progression. 
7. Converging pathways of COX and LOX in HNC 
The AA-metabolizing enzymes are overexpressed during animal and human carcinogenesis 
and   AA metabolites such as PGE2, 5-HETE and LTB4 had been implicated in HNC 
development. COX-2 and 5-LOX play important roles in inflammation and inflammation-
associated tumorigenesis. It is evident that COX and LOX display similarities in expression 
and functions in HNC. In particular, the COX-2 and 5-LOX pathways are activated together 
during inflammation, and blocking one pathway may activate the other. It was shown that 
inhibition of COX-2 might lead to a shunt of AA metabolism towards the LT pathway in 
HNC. Suppressing PGE2 levels by a COX-2 inhibitors, celecoxib, leads to an increase in the 
activity of 5-LOX, 12-LOX and 15-LOX-2 and results in the increase of their products, 
including, 5-HETE, 12-HETE and 15-HETE (Schroeder et al., 2004).  A study in the mouse 
model of HNC, demonstrated an increase of LTB4 in tumor tissues in mice treated with 
PGE2. In contrast, LTB4 could not decrease tumor tissue levels of PGE2 (Scioscia et al., 2000). 
Therefore, simultaneous blocking of each enzyme may be required to achieve  
substantial elevation in free AA levels and prevent the shunting of metabolism to another 
active pathway. 
Taken together, COX-2 and 5-LOX may have redundant function in HNC pathobiology. 
First, COX-2 and 5-LOX enhance tumor cell proliferation. Second, both COX-2 and 5-LOX 
are proangiogenic with a convergent targeting on VEGF, FGF and MMPs. Third, COX-2 as 
well as 5-LOX inhibitors, arrest cell cycle progression and induce apoptotic cell death in 
HNSCC cells. Fourth, both COX-2 and 5-LOX enhance HNSCC cell invasion and tumor 
metastasis. In addition, active COX2 and 5-LOX are localized in the nucleus, and they may 
function as endogenous ligands for nuclear receptors such as the PPARs (Menna et al.; 
Romano & Claria, 2003) (Figure 3). 
8. Future prospects and conclusions 
The summarized findings contained in this review support the contributory role of chronic 
inflammation in the pathogenesis of HNC. A hallmark of the inflammatory process is the 
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synthesis of inflammatory cytokines and AA metabolites. Two major AA metabolic routes, 
i.e., the COX and LOX pathways control the biosynthesis of eicosanoid. COX-derived 
eicosanoids comprise PG and TXA2, whereas HPETE and LTs are products of LOX-
catalyzed arachidonic acid metabolism. In HNC, COX-2 and LOX are coexpressed and 
upregulated in tumor cell lines, experimentally induced animal tumor models and human 
tumor biopsies. Currently, the underlying mechanisms for the tumorigenic effects of COX 
and LOX remain somewhat undefined. A number of studies of HNC have suggested the 
involvement of COX-2 and/ or 5-LOX in tumor cell proliferation, apoptosis, angiogenesis 
and metastasis. 
 
Fig. 3. Effects of COXs and LOXs on tumerigenesis. Both COXs and LOXs stimulate 
proliferation, inhibit apoptosis, induce angiogenesis, and enhance invasion and metastasis 
in cancer cells. MAPKs: mitogen activated protein kinases; PKC: protein kinase C; Bcl-2: B-
cell lymphoma2; PPARs: peroxisome proliferator-activated receptor; VEGF: vascular 
endothelial growth factor; MMP: matrix metalloproteinase. 
COX and/ or LOX inhibitors in many instances demonstrate potent anticancer effects. 
Manipulation of AA metabolism, therefore, represents a promising approach to develop 
HNC therapy. However, in spite of extensive research in COX and LOX inhibitors, their 
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combined use for chemoprevention is still in its development stage. Further investigations 
are indeed necessary to develop appreciate chemopreventive strategies in HNC. First, the 
mechanism by which COX and LOX pathways are deregulated, interacted with each other, 
or contribute to head and neck tumorigenesis must be more clarified. Second, more clinical 
studies are critical to evaluate the effectiveness of COX and LOX inhibitors and to 
understand their mechanisms of action a single agent and in combination in HNC, 
specifically. Eventually, possible drug toxicity from a combined use must be evaluated over 
the long term. 
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